Eliminating epidemic meningitis as a public health problem in sub-Saharan Africa

Introduction and impact of a new group A meningococcal conjugate vaccine in Africa The Meningitis Vaccine Project (MVP) began its history back in early 2000 when a WHO expert concluded that the development of a meningococcal conjugate vaccine offered an opportunity for epidemic control in sub-Saharan Africa. In April 2000, a group of international experts and delegates from African ministries …

Meningitis Vaccine Project: working to eliminate epidemic meningitis in sub-Saharan Africa

Following the meningitis epidemic of 1996, African public health officials asked WHO to help them address the problem. Conjugate meningococcal vaccines were recommended following international meetings in 2000 and 2001. The Meningitis Vaccine Project was created in June 2001 to develop, test, license and implement the widespread use of conjugate meningococcal vaccines in Africa.  Dr Marc LaForce, Meningitis Vaccine Project …

#wvcusa Marc LaForce discussing now early impact results after the introduction of a new Group A meningococcal conjugate #vaccine in Africa

Meningococcal vaccine: Today at World Vaccine Congress Washington, Dr Marc LaForce, Director, Meningitis Vaccine Project, PATH delivered a great presentation about the Impact data on vaccine mass-introduction to Sub-Saharan countries. Some Key points raised in the presentation: Overview of epidemic meningitis in Africa: Major epidemics of meningitis occur in the ‘meningitis belt' of sub-Saharan Africa and one strain is responsible …